Trial record 1 of 1 for:    NCT01268865
Previous Study | Return to List | Next Study

Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by China Medical University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01268865
First received: December 30, 2010
Last updated: June 2, 2011
Last verified: June 2011

December 30, 2010
June 2, 2011
December 2010
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01268865 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis
Clinical Application of Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis in HBV and HCV-infected Patients

Background: In patients with chronic liver diseases, liver fibrosis staging is crucial for hazard evaluation of future disease complication development and thus for the optimal decision making on treatment selections.In the era of antiviral and antifibrotic treatments, clinical and research demands are also increasing for non-invasive surveillance of liver fibrosis to evaluate the progression or regression. However, local baseline data on liver stiffness measurement (LSM) using ARFI technique is still lacking in Taiwan, where viral hepatitides are highly endemic. Aim: Using the ARFI elastosonography, we are dedicated to the aims to recruit patients based on strict but appropriate criteria, to complete the correlation and validity studies between ARFI quantification and the referenced METAVIR fibrosis scoring and to conduct subsequent innovative studies on liver diseases. Materials and Methods: We plan to perform the ARFI quantification for each HBV or HCV-infected patient immediately followed by priorly scheduled conventional liver biopsy for METAVIR scoring during the same session of examination. Statistics: The first year's study using ARFI will focus on the correlation testings and validity studies using receiver operating characteristics.

Contribution and Future Works: Using the ARFI quantification either as a causal factor or as a outcome, we can conduct future analyses ranging from validations, regressions to prospective time-to-event analysis among our cohorts.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

HBV or HCV-infected patients about to undergo liver biopsy to assist in clinical decision making

Liver Fibrosis
Not Provided
  • HBV-infected
  • HCV-infected
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
Not Provided
Not Provided

Inclusion Criteria:

  • infected with HBV only or HCV only

Exclusion Criteria:

  • concurrent HBV-HCV infection, etc.
Both
18 Years to 75 Years
Yes
Contact: Sheng-Hung Chen, MD 886-4-22052121 ext 2264 shcvghtc@gmail.com
Taiwan
 
NCT01268865
DMR99-IRB-240
Yes
Sheng-Hung Chen, China Medical University Hospital
China Medical University Hospital
Not Provided
Principal Investigator: Sheng-Hung Chen, MD Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital
Study Director: Cheng-Yuan Peng, MD, PhD Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital
China Medical University Hospital
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP